
Kymab makes two senior appointments
pharmafile | June 5, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | arkinstall, clark, kymab
Cambridge-based biopharma firm Kymab has hired Steve Arkinstall as a chief scientific officer, and Nigel Clark as VP and head of business development.
Clark (pictured) has 20 years’ experience in the biopharma industry at both public and private companies. He was previously a chief business officer at Syntaxin, and prior to that was head of business development at Vernalis for seven years.
Arkinstall takes overs 25 years’ experience to the firm spanning biopharmaceutical R&D, and having worked across several disease and specialist areas.
He joins Kymab from Merck Serono, where over his 16-year career he has held a number of senior management roles including leadership of the Serono Research Institute in Boston, as well as head of global technologies and external innovation.
Christian Groendahl, chief executive of Kymab, says: “We are delighted to announce the appointments of Steve and Nigel to Kymab’s senior management team. We look forward to benefiting from both Steve and Nigel’s experience as we build Kymab into a global biotechnology company.”
Related Content

Sanofi to acquire Kymab for $1.1bn
Sanofi is to acquire clinical-stage biopharmaceutical company Kymab for approximately $1.1 billion. In addition to …

Chinese investors push Kymab backing to $100 million
Kymab, the UK-based antibody biopharmaceutical group, announced that it has secured $100 million in funding. …

Kymab demonstrates promising research for HIV vaccine development
Cambridge-based antibodies-to-medicines company Kymab has announced publication of research testing the first step in the …






